Rapid advancements in the science of chimeric antigen receptor (CAR) T-cell therapies present unique challenges and opportunities related to patient care. Nurses are at the forefront of those advancements—contributing to practice guidelines, developing center-specific protocols, publishing outcomes and best practices, and researching the patient experience, outcomes, and supportive interventions.

On May 4, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu^®) for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2–based regimen in the metastatic setting as well as those in the neoadjuvant or adjuvant setting who developed disease recurrence during or within six months of completing therapy.

A single patient. A team of nurses providing compassionate, patient-centered care. A family so thankful that it had to give back. Today, it’s touched more than 177,000 nurses around the world in recognition of what they do every day: deliver high-quality, transformational cancer care.

As the U.S. Food and Drug Administration (FDA) continues its review of tobacco and e-cigarette products’ marketing applications, legislators and government officials, such as Energy and Commerce Committee Chair Frank Pallone, Jr. (D-NJ), are taking a stand and sharing their concerns on Big Tobacco’s marketing to teenage audiences.

The interprofessional team for chimeric antigen receptor (CAR) T-cell therapy at Smilow Cancer Center at Yale New Haven includes a transplant team, cell collection and processing unit, intensive care unit, pharmacy, telehealth for home evaluations, and social work. On that team, the oncology clinical social worker’s role is chiefly to help patients and families manage the stress associated with therapy. We provide patients and family members with ongoing clinical social work support, including listening, counseling, educating, advocating, and referring them to resources and services.

National Cancer Institute (NCI) Director Norman Sharpless, MD, announced his decision to step down as the institute’s director in April 2022, a position he has held since 2017. According to NCI, the institute’s principal deputy director, Douglas R. Lowy, MD, will serve as acting director at the end of the month.

Nearly a quarter of patients who are eligible for cervical cancer screening are overdue for their current tests, researchers said in study findings published in JAMA Network Open. The number grew nearly 10% since 2005—representing a steady increase in missed screening over time—and was higher in different sociodemographic groups because of factors related to social determinants of health.

People who use electronic cigarettes have unique microbial communities in their mouths that more closely resembled those of smokers than nonsmokers, which may signal an increased risk of gum disease for those individuals, according to findings from research funded in part by the National Institute of Health’s (NIH’s) National Institute of Dental and Craniofacial Research.

Debuting in human clinical trials just a decade ago, chimeric antigen receptor (CAR) T-cell therapy was quickly hailed as a breakthrough cancer treatment for certain hematologic cancers. Today, patients and providers have access to 22 U.S. Food and Drug Administration (FDA)–approved cellular and gene therapy products, and CAR T-cell therapy is available beyond large academic research centers.

Virtual appointments and other telehealth care allow patients and families to have ready access to cancer care from the comfort of their own home, Kevin M. Curtis, MD, medical director of the Center for Telehealth at Dartmouth-Hitchcock Health, said in a March 2022 National Cancer Institute (NCI) blog post praising the service. Curtis also highlighted telehealth’s role in addressing health disparities, its high satisfaction rate with both patients and clinicians, and the service’s future in cancer care research.